While this happened, Morgan Stanley downgraded its Celularity Inc [CELU] rating to an Underweight from a an Equal-weight in a research note published on January 30, 2023; the price target was decreased to $1 from $5. A number of analysts have revised their coverage, including Oppenheimer’s analysts, who decreased its forecast for the stock in late December from “an Outperform” to “a Perform”. H.C. Wainwright began covering CELU with “Buy” recommendation on June 22, 2022. Truist revised its rating on April 06, 2022. It rated CELU as “a Hold” which previously was an “a Buy”.
Price Performance Review of CELU
On Tuesday, Celularity Inc [NASDAQ:CELU] saw its stock jump 23.03% to $1.87. Over the last five days, the stock has gained 10.65%. Celularity Inc shares have fallen nearly -10.10% since the year began. Nevertheless, the stocks have fallen -38.69% over the past one year. While a 52-week high of $5.22 was reached on 02/05/25, a 52-week low of $1.00 was recorded on 03/04/25. SMA at 50 days reached $1.5941, while 200 days put it at $2.2420.
Levels Of Support And Resistance For CELU Stock
The 24-hour chart illustrates a support level at 1.5787, which if violated will result in even more drops to 1.2873. On the upside, there is a resistance level at 2.1827. A further resistance level may holdings at 2.4953. The Relative Strength Index (RSI) on the 14-day chart is 60.82, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0677, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 44.89%. Stochastics %K at 41.75% indicates the stock is a holding.
The most recent change occurred on January 28, 2022 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $9 price target.
